 CAMBRIDGE, Mass., May 12, 2021 GLOBE NEWSWIRE -- Fulcrum Therapeutics, Inc. Nasdaq: FULC, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the U.S. Food and Drug Administration FDA has granted Fast Track designation to losmapimod for the potential treatment of facioscapulohumeral muscular dystrophy FSHD. 